Meghívásos bevonás
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy(PRECAL)
NCT07721441· Tang-Du Hospital· Forrás
Toboroz
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07552402· Harbin Medical University· Forrás
Contact: Tao Wu
Toboroz
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200· 1. fázis· Candid Therapeutics· Forrás
Contact: Martin Zhuang
Toboroz
Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)
NCT07389460· 3. fázis· First Affiliated Hospital Xi'an Jiaotong University· Forrás
Contact: Linyun Zhang, MD
Toboroz
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236· 2. fázis· Fujian Cancer Hospital· Forrás
Contact: Qin Xu, Ph.D
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Contact: Clinical Trials
Még nem toboroz
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
NCT07292896· First Hospital of China Medical University· Forrás
Contact: Jun Wu
Még nem toboroz
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Xiuhua Sun, Master
Toboroz
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· 2/3. fázis· Pfizer· Forrás
Toboroz
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311· 2. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: Man Li, Doctor
Toboroz
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Man Li, Doctor
Toboroz
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
NCT07087223· 1/2. fázis· Peking University Cancer Hospital & Institute· Forrás
Contact: Minglei Zhuo
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· 3. fázis· Jiangsu Simcere Pharmaceutical Co., Ltd.· Forrás
Fut, nem toboroz
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532· 3. fázis· Biotheus Inc.· Forrás
Fut, nem toboroz
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Toboroz
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558· 2. fázis· Shanghai SIMR Biotechnology Co., Ltd.· Forrás
Contact: Wang, PhD
Toboroz
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules
NCT06423235· 4. fázis· Xintian Pharmaceutical· Forrás
Contact: Wenjing Ji
Fut, nem toboroz
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· 3. fázis· Biotheus Inc.· Forrás
Toboroz
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994· 3. fázis· InnoCare Pharma Inc.· Forrás
Contact: Xiuhua Sun
Toboroz
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138· 2/3. fázis· Beijing InnoCare Pharma Tech Co., Ltd.· Forrás
Contact: Xiuhua Sun
Toboroz
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729· 2. fázis· Hansoh BioMedical R&D Company· Forrás
Contact: Siwei Bao
Toboroz
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686· 2. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás
Contact: Coordinator
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Contact: Man Li
Toboroz
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Liming Wang, Doctor
Toboroz
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
NCT05918094· 3. fázis· Sun Yat-sen University· Forrás
Contact: Jinghua Sun
Fut, nem toboroz
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087· 2. fázis· Guangzhou Lupeng Pharmaceutical Company LTD.· Forrás
Fut, nem toboroz
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679· Amgen· Forrás
Fut, nem toboroz
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT07226752· 3. fázis· Genmab· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· 3. fázis· Shanghai Henlius Biotech· Forrás
Fut, nem toboroz
Long-term Efficacy and Safety Study of GV-971
NCT05181475· 4. fázis· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Forrás
Fut, nem toboroz
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499· 1/2. fázis· Klus Pharma Inc.· Forrás
Fut, nem toboroz
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230· 3. fázis· BeiGene· Forrás